1.09
-0.02(-1.80%)
Currency In USD
Address
2265 Upper Middle Road East
Oakville, ON L6H 0G5
Canada
Phone
289 910 0850
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
First IPO Date
January 15, 2019
| Name | Title | Pay | Year Born |
| Mr. David G. Elsley MBA | President, Chief Executive Officer & Director | 564,307 | N/A |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | Chief Financial Officer, Corporate Secretary & Director | 220,707 | N/A |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer | 386,237 | N/A |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research & Development | 564,388 | 1962 |
| Mr. John A. Geddes BSCPT, MBA | Vice President of Corporate Development | 0 | N/A |
| Trevor Burns | Investor Relations | 0 | N/A |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.